118 related articles for article (PubMed ID: 30986571)
1. Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies.
Tong L; Song P; Jiang K; Xu L; Jin T; Wang P; Hu X; Fang S; Gao A; Zhou Y; Liu T; Li J; Hu Y
Eur J Med Chem; 2019 Jul; 173():44-62. PubMed ID: 30986571
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile.
Jin T; Xu L; Wang P; Hu X; Zhang R; Wu Z; Du W; Kan W; Li K; Wang C; Zhou Y; Li J; Liu T
J Med Chem; 2021 Oct; 64(20):15069-15090. PubMed ID: 34665631
[TBL] [Abstract][Full Text] [Related]
3. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
Osborne JD; Matthews TP; McHardy T; Proisy N; Cheung KM; Lainchbury M; Brown N; Walton MI; Eve PD; Boxall KJ; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Jamin Y; Robinson SP; Westwood IM; van Montfort RL; Leonard PM; Lamers MB; Reader JC; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2016 Jun; 59(11):5221-37. PubMed ID: 27167172
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies.
Jiang KL; Tong LX; Wang T; Wang HL; Hu XB; Xu GY; Jin TT; Kan WJ; Xu L; Li JN; Zhang KX; Song N; Liu JY; Zhang MM; Wu WB; Xiang YQ; Gao AH; Hu YZ; Zhou YB; Liu T; Yang JM; Li J
Acta Pharmacol Sin; 2022 Jan; 43(1):220-228. PubMed ID: 33782542
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1
Oh Y; Jang M; Cho H; Yang S; Im D; Moon H; Hah JM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):372-376. PubMed ID: 31856610
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Pyrrolo[2,3-
Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2018 May; 151():836-848. PubMed ID: 29684894
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of 2-Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors.
Deng M; Wang P; Long X; Xu G; Wang C; Li J; Zhou Y; Liu T
ChemMedChem; 2023 Apr; 18(7):e202200664. PubMed ID: 36732891
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling, molecular docking and molecular dynamics simulations toward identifying lead compounds for Chk1.
Li Y; Peng J; Zhou Y; Li P; Li Y; Liu X; Siddique AN; Zhang L; Zuo Z
Comput Biol Chem; 2018 Oct; 76():53-60. PubMed ID: 29940486
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors.
Malvacio I; Cuzzolin A; Sturlese M; Vera DMA; Moyano EL; Moro S
J Enzyme Inhib Med Chem; 2017 Dec; 33(1):171-183. PubMed ID: 29210298
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors.
Song P; Peng P; Han M; Cao X; Ma X; Liu T; Zhou Y; Hu Y
Bioorg Med Chem; 2014 Sep; 22(17):4882-92. PubMed ID: 25042558
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1H-pyrazol-4 -amine derivatives as novel and potent syk inhibitors for the treatment of hematological malignancies.
Cui B; Wang Y; Zhao Z; Fan L; Jiao Y; Li H; Feng J; Tang W; Lu T; Chen Y
Eur J Med Chem; 2023 Oct; 258():115597. PubMed ID: 37423126
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.
Tao ZF; Li G; Tong Y; Stewart KD; Chen Z; Bui MH; Merta P; Park C; Kovar P; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5944-51. PubMed ID: 17827013
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H; Nair SK; Murray BW; Almaden C; Bailey S; Baxi S; Behenna D; Cho-Schultz S; Dalvie D; Dinh DM; Edwards MP; Feng JL; Ferre RA; Gajiwala KS; Hemkens MD; Jackson-Fisher A; Jalaie M; Johnson TO; Kania RS; Kephart S; Lafontaine J; Lunney B; Liu KK; Liu Z; Matthews J; Nagata A; Niessen S; Ornelas MA; Orr ST; Pairish M; Planken S; Ren S; Richter D; Ryan K; Sach N; Shen H; Smeal T; Solowiej J; Sutton S; Tran K; Tseng E; Vernier W; Walls M; Wang S; Weinrich SL; Xin S; Xu H; Yin MJ; Zientek M; Zhou R; Kath JC
J Med Chem; 2016 Mar; 59(5):2005-24. PubMed ID: 26756222
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia.
Jin T; Wang P; Long X; Jiang K; Song P; Wu W; Xu G; Zhou Y; Li J; Liu T
ChemMedChem; 2021 May; 16(9):1477-1487. PubMed ID: 33591599
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
19. Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.
Yang B; Vasbinder MM; Hird AW; Su Q; Wang H; Yu Y; Toader D; Lyne PD; Read JA; Breed J; Ioannidis S; Deng C; Grondine M; DeGrace N; Whitston D; Brassil P; Janetka JW
J Med Chem; 2018 Feb; 61(3):1061-1073. PubMed ID: 29301085
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.
Tao ZF; Li G; Tong Y; Chen Z; Merta P; Kovar P; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Aug; 17(15):4308-15. PubMed ID: 17544271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
